Specific Biomarkers for Detection of Cervical Cancer Cells Using Flow Cytometry

使用流式细胞术检测宫颈癌细胞的特异性生物标志物

基本信息

批准号：
7186773
负责人：
JOSEPH PAUL ROBINSON
金额：
$ 18.59万
依托单位：
PURDUE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-12-18 至 2008-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7186773
关键词：
Abnormal Cell Address Adopted Affinity Antibodies Area Biological Markers Biopsy Biotinylation Blood Cells CDKN2A gene Cancerous Categories Cell Count Cell Separation Cells Cervical Cervical Cancer Screening Clinical Color Condition Cytology Cytopathology D Cells Data Death Rate Detection Developed Countries Developing Countries Devices Diagnostic Procedure Disease Dissociation Event Failure Flow Cytometry Fluorescence Fluorescent Antibody Technique Future Goals Hela Cells Image Imaging technology Immunofluorescence Immunologic Immunohistochemistry Incidence Individual Lead Lesion Liquid substance Malignant - descriptor Malignant Neoplasms Malignant neoplasm of cervix uteri Measurement Measures Methods Microscopic Modification Mus Noise Normal Cell Numbers Pap smear Phycoerythrin Population Premalignant Preparation Procedures Process Rate Research Personnel Sampling Screening procedure Sensitivity and Specificity Signal Transduction Sorting - Cell Movement Specimen Staining method Stains Suspension substance Suspensions Techniques Technology Testing Time Validation Visual Woman allophycocyanin base cancer cell cell fixation experience fluorescence imaging improved instrument instrumentation malignant breast neoplasm mortality novel novel strategies programs systems research technology development

项目摘要

DESCRIPTION (provided by applicant): Cervical cancer is second to breast cancer as the most common form of malignancy in both incidence and mortality for women worldwide. The pap smear test and liquid-based cytology have been adopted as population-wide cervical cancer screening programs in the U.S. and other developed countries. In the US, this screening program has led to a remarkable reduction in the incidence and mortality rate of cervical cancer, from 26,000 in 1941 to 4,600 in 2000. However, the current method of cervical cancer screening is still subjective and labor intensive in the detection of abnormal cells from large number of normal cells. This application proposes a new approach of involving specific biomarkers and high throughput flow cytometry for the detection of rare abnormal cells. Abnormal cells will be captured and separated from normal cells using flow sorting and based on their expression levels of precancerous biomarkers. The development of this technology could lead to a high throughput, biomarker driven clinical device for routine cervical cancer screening in the future.

描述（由申请人提供）：对于全世界女性来说，无论是发病率还是死亡率，宫颈癌都是仅次于乳腺癌的最常见的恶性肿瘤。美国和其他发达国家已采用子宫颈抹片检查和液基细胞学检查作为全民宫颈癌筛查计划。在美国，这项筛查计划使宫颈癌的发病率和死亡率显着下降，从1941年的26,000人下降到2000年的4,600人。然而，目前的宫颈癌筛查方法在检测方面仍然存在主观性和劳动强度。从大量正常细胞中分离出异常细胞。该申请提出了一种涉及特定生物标志物和高通量流式细胞术的新方法，用于检测罕见的异常细胞。使用流式分选并根据癌前生物标志物的表达水平捕获异常细胞并将其与正常细胞分离。这项技术的发展可能会带来高通量、生物标志物驱动的临床设备，用于未来的常规宫颈癌筛查。